FundedIQ
Biotechnology

Venatorx Pharmaceuticals: Funding, Investors & Team (Sep 2026)

VenatoRx is a private pharmaceutical company focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant bacterial infections and hard-to-treat viral infections. Founded in 2010, VenatoRx has built a world-class in-house R&D organization that has filed over 100 patents spanning multiple research programs. It has received significant funding awards from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH); Wellcome Trust; the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Service (HHS); the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA); and CARB-X, and as well as private equity investments from Versant Ventures, Abingworth, and Foresite Capital.

www.venatorx.com LinkedIn Malvern, United States 51-100 employees
Biotechnology Health Care Medical Pharmaceutical
Total raised
$11.7M
Rounds
2
Latest
Undisclosed round
Sep 2022

Venatorx Pharmaceuticals has raised $11.7M across 2 funding rounds on record, the most recent an undisclosed round of $11.7M announced in Sep 2022.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Venatorx Pharmaceuticals Company Profile and Key Stats

Total funding raised
$11.7M
across 2 rounds on record
Funding rounds on record
2
1 with no disclosed amount
Latest funding round
Undisclosed round
$11.7M in Sep 2022
Employees
51-100
reported band
Headquarters
Malvern, United States

Latest funding round on record: Sep 2022.

Venatorx Pharmaceuticals Funding Rounds

Date
Round
Amount
Undisclosed round
$11.7M
Series C
Undisclosed

1 of 2 rounds was announced without a disclosed amount and is excluded from the total.

Venatorx Pharmaceuticals announced a Series C in Apr 2022; the amount was not disclosed.

5 months later, an undisclosed round of $11.7M was announced in Sep 2022.

Venatorx Pharmaceuticals Founders and Leadership Team

Name
Role
Contact
Luigi Xerri
Founder
Locked
Christopher Burns
CEO
Locked

Contact details for the Venatorx Pharmaceuticals team: 2 of 2 have an email address on file.

Start 14-day free trial →

Venatorx Pharmaceuticals Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,179
$8.0M
29,722
$7.5M

Venatorx Pharmaceuticals' latest round of $11.7M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Venatorx Pharmaceuticals in Biotechnology and Malvern

Companies Similar to Venatorx Pharmaceuticals

Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…

Convertible Note $6.8M

XiltriX North America is an information technology company that specializes in monitoring, predictive…

Undisclosed round $3.0M

Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…

Seed $3.1M

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…

Series D $66.0M

Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…

Series B $92.7M

Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…

Series C $110M

InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…

Series B $77.0M

Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…

Series A $6.3M

Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.

Series C $90.0M

Cataract surgery is the single most common procedure performed in the United States annually. Despite…

Series A $7.0M

InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…

Convertible Note $1.3M

Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…

Series A $10.0M

Venatorx Pharmaceuticals Funding FAQs

What does Venatorx Pharmaceuticals do?

VenatoRx is a private pharmaceutical company focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant bacterial infections and hard-to-treat viral infections. Founded in 2010, VenatoRx has built a world-class in-house R&D organization that has filed over 100 patents spanning multiple research programs. It has received significant funding awards from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH); Wellcome Trust; the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Service (HHS); the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA); and CARB-X, and as well as private equity investments from Versant Ventures, Abingworth, and Foresite Capital.

How much funding has Venatorx Pharmaceuticals raised?

Venatorx Pharmaceuticals has raised $11.7M across 2 rounds on record. The most recent is an undisclosed round of $11.7M announced in Sep 2022.

When did Venatorx Pharmaceuticals last raise funding?

Venatorx Pharmaceuticals' most recent funding round on record is an undisclosed round of $11.7M, announced in Sep 2022.

Who founded Venatorx Pharmaceuticals?

FundedIQ lists Luigi Xerri (Founder) at Venatorx Pharmaceuticals.

Who is the CEO of Venatorx Pharmaceuticals?

Christopher Burns is listed as CEO at Venatorx Pharmaceuticals.

Where is Venatorx Pharmaceuticals headquartered?

Venatorx Pharmaceuticals is based in Malvern, Pennsylvania, United States.

How many employees does Venatorx Pharmaceuticals have?

Venatorx Pharmaceuticals is in the 51-100 employee band.

How does Venatorx Pharmaceuticals' funding compare to other Biotechnology startups?

Venatorx Pharmaceuticals' latest round of $11.7M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.

About FundedIQ's Venatorx Pharmaceuticals Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Venatorx Pharmaceuticals is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.